ATE135002T1 - Wasserlösliche derivate von taxol mit antineoplastischer aktivität - Google Patents

Wasserlösliche derivate von taxol mit antineoplastischer aktivität

Info

Publication number
ATE135002T1
ATE135002T1 AT92308421T AT92308421T ATE135002T1 AT E135002 T1 ATE135002 T1 AT E135002T1 AT 92308421 T AT92308421 T AT 92308421T AT 92308421 T AT92308421 T AT 92308421T AT E135002 T1 ATE135002 T1 AT E135002T1
Authority
AT
Austria
Prior art keywords
taxol
cyz
synthesized
group
reacting
Prior art date
Application number
AT92308421T
Other languages
English (en)
Inventor
David G I Kingston
State Uni Inst
Zhi-Yang Zhao
Uni State
Original Assignee
Virginia Tech Intell Prop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intell Prop filed Critical Virginia Tech Intell Prop
Application granted granted Critical
Publication of ATE135002T1 publication Critical patent/ATE135002T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92308421T 1991-10-15 1992-09-16 Wasserlösliche derivate von taxol mit antineoplastischer aktivität ATE135002T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/774,107 US5278324A (en) 1990-08-28 1991-10-15 Water soluble derivatives of taxol

Publications (1)

Publication Number Publication Date
ATE135002T1 true ATE135002T1 (de) 1996-03-15

Family

ID=25100263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92308421T ATE135002T1 (de) 1991-10-15 1992-09-16 Wasserlösliche derivate von taxol mit antineoplastischer aktivität

Country Status (13)

Country Link
US (1) US5278324A (de)
EP (1) EP0537905B1 (de)
KR (1) KR930007925A (de)
AT (1) ATE135002T1 (de)
CA (1) CA2080393A1 (de)
CZ (1) CZ312292A3 (de)
DE (1) DE69208802T2 (de)
DK (1) DK0537905T3 (de)
ES (1) ES2086669T3 (de)
FI (1) FI924678L (de)
GR (1) GR3020109T3 (de)
NZ (1) NZ244754A (de)
PL (2) PL299303A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5973160A (en) 1992-12-23 1999-10-26 Poss; Michael A. Methods for the preparation of novel sidechain-bearing taxanes
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
TW467896B (en) 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6005120A (en) 1993-07-20 1999-12-21 Florida State University Tricyclic and tetracyclic taxanes
AU8052194A (en) * 1993-10-20 1995-05-08 Enzon, Inc. 2'- and/or 7- substituted taxoids
DE69527346T2 (de) * 1994-01-11 2003-02-13 The Scripps Research Institute, La Jolla Sich selbst bildende taxo-diterpenoid nanostrukturen
GB9405400D0 (en) * 1994-03-18 1994-05-04 Erba Carlo Spa Taxane derivatives
US5801191A (en) * 1995-06-01 1998-09-01 Biophysica Foundation Taxoids
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
ATE309235T1 (de) * 1995-09-12 2005-11-15 Zeneus Pharma Ltd Hydrolyse-einleitende hydrophobe taxane derivate
US6051600A (en) * 1995-09-12 2000-04-18 Mayhew; Eric Liposomal hydrolysis-promoting hydrophobic taxane derivatives
EP1229030B1 (de) * 1995-09-12 2005-11-09 Zeneus Pharma Limited Hydrolyse-einleitende hydrophobe Taxane Derivate
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US5854278A (en) * 1995-12-13 1998-12-29 Xechem International, Inc. Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents
US5807888A (en) * 1995-12-13 1998-09-15 Xechem International, Inc. Preparation of brominated paclitaxel analogues and their use as effective antitumor agents
US6177456B1 (en) 1995-10-02 2001-01-23 Xechem International, Inc. Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor
US5840748A (en) * 1995-10-02 1998-11-24 Xechem International, Inc. Dihalocephalomannine and methods of use therefor
US5654448A (en) * 1995-10-02 1997-08-05 Xechem International, Inc. Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
GB9705903D0 (en) 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
CZ2003837A3 (cs) * 2000-09-22 2004-12-15 Bristol-Myers Squibb Company Způsob pro snížení toxicity při kombinovaných chemoterapiích
CA2440935A1 (en) 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (de) 2001-03-23 2005-05-11 Luitpold Pharm Inc Fettamin-arzneimittel-konjugate
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
PL368945A1 (en) 2001-11-30 2005-04-04 Bristol-Myers Squibb Company Paclitaxel solvates
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
AU2003225495B2 (en) * 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
US20040254419A1 (en) * 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
US20070010702A1 (en) * 2003-04-08 2007-01-11 Xingwu Wang Medical device with low magnetic susceptibility
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
WO2005061710A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
WO2006050732A2 (en) * 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
MX2007005558A (es) * 2004-11-09 2008-01-31 Santaris Pharma As Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
EP1832577A1 (de) * 2006-03-07 2007-09-12 Sanofi-Aventis Verbesserte Pro-Pharmaka von CC-1065-Analoga
EP2029156A4 (de) * 2006-05-01 2010-07-21 Univ Southern California Kombinationstherapie zur krebsbehandlung
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
WO2009090614A2 (en) * 2008-01-16 2009-07-23 Anwar Rayan Derivatives of taxol and closely related compounds
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
US8642063B2 (en) * 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol

Also Published As

Publication number Publication date
US5278324A (en) 1994-01-11
ES2086669T3 (es) 1996-07-01
DK0537905T3 (da) 1996-07-22
FI924678A0 (fi) 1992-10-15
PL299303A1 (en) 1994-01-10
FI924678A7 (fi) 1993-04-16
DE69208802D1 (de) 1996-04-11
CZ312292A3 (en) 1993-05-12
GR3020109T3 (en) 1996-08-31
EP0537905B1 (de) 1996-03-06
KR930007925A (ko) 1993-05-20
DE69208802T2 (de) 1996-10-02
FI924678L (fi) 1993-04-16
PL296256A1 (en) 1993-10-18
NZ244754A (en) 1995-03-28
EP0537905A1 (de) 1993-04-21
CA2080393A1 (en) 1993-04-16

Similar Documents

Publication Publication Date Title
ATE135002T1 (de) Wasserlösliche derivate von taxol mit antineoplastischer aktivität
CA2049160A1 (en) Water soluble derivatives of taxol
DK0415456T3 (da) Xanthinforbindelser
RU99117921A (ru) Аминосоединение для получения новых производных пиридонкарбоновой кислоты или их солей
DE69033614D1 (de) Kondensierte Purinderivate
NO302755B1 (no) Morfinan-derivater
KR830005212A (ko) 이미다조[1,2-α] 피리딘의 제조방법
ATE105285T1 (de) Salicylaldehyd- und salicylsaeurederivate sowie deren schwefelanaloge, verfahren zu ihrer herstellung und ihre verwendung als herbizide und bioregulatoren.
RU2001130457A (ru) Способ получения аминоплатиновых комплексов
ATE132152T1 (de) Verwendung von kupfer-komplexen von alpha- aminsäuren mit terminalen amino-gruppen als nahrungsmittelzusatz
KR930702312A (ko) 피리미딘 유도체 및 의약
DK0466137T3 (da) Salte af triazinderivater med oxygenerede syrer af phosphor og deres anvendelse i selvslukkende polymersammensætninger
EP0736523A3 (de) Zirkonverbindungen von Sulfonsäuren
CA2019704A1 (en) N,n-disubstituted phthalamic acids and their ammonium salts, and their uses thereof as surfactants, emulsifiers, and conditioning agents in shampoos
DE59510442D1 (de) Sulfonsäuregruppen enthaltende Polyasparaginsäurederivate, ihre Verwendung und Herstellung
WO1999035133A3 (en) 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid derivatives as chelating agents
DE3770724D1 (de) Thiazolidin-4-one-derivate un deren saeure-additionssalze.
PT1213279E (pt) Processo para a preparacao de venlafaxina
DE69119714D1 (de) Verfahren zur Herstellung von Benzylphthalazinonderivaten und von deren Salzen
DK727488D0 (da) Benzimidazolderivater og farmaceutisk acceptable salte deraf, deres fremstilling og anvendelse
DK189291A (da) 3h-purin-2,6-dionderivater og salte deraf, farmaceutisk praeparat indeholdende dem samt fremstilling af derivater og praeparat
EP1283210A4 (de) Verfahren zur herstellung von sulfonamidderivaten und ihrer kristalle
TR200100178T2 (tr) Yeni 6-deoksi eritromisin türevleri, bunların hazırlanmasına yönelik metod
JPS5738805A (en) Production of dried cationic polymer
TH25517A (th) ผลิตภัณฑ์ของผสมเติมซีเมนต์ที่พัฒนาขึ้น

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee